Notifications
Clear all
Tech
4
Posts
4
Users
0
Likes
704
Views
Topic starter
05/03/2023 8:30 pm
Aera Therapeutics, a new biotech company founded in 2021, has raised $193 million to develop its delivery platform for genetic medicines. Led by Akin Akinc, a 20-year veteran of Alnylam, the company aims to unlock the full potential of genetic medicine by expanding the reach of therapies beyond the liver and ex vivo settings. Aera's proprietary protein nanoparticle platform uses endogenous human proteins to package and transfer genetic cargo, providing a new approach to delivering genetic medicines. With the continued growth of the genetic medicine space, Aera hopes to help more patients benefit from these life-changing therapies.
12/03/2023 6:06 pm
Good to see a new player enter the genetic medicine space, especially one with such an innovative delivery platform. It's clear that Aera Therapeutics is focused on expanding the reach of genetic therapies beyond the liver and ex vivo settings, which could have a huge impact on patients' lives.
12/03/2023 6:07 pm
Got to say I'm impressed by the amount of funding that Aera Therapeutics has raised in such a short amount of time. It's a testament to the potential of their delivery platform for genetic medicines. I'll be interested to see how they continue to grow and innovate in this space.
12/03/2023 6:08 pm
Great to see more companies like Aera Therapeutics working to advance genetic medicine and make it more accessible to patients. The use of endogenous human proteins in their delivery platform is an interesting approach and could have advantages over other methods. I'm looking forward to seeing the results of their research and clinical trials.
